 | • レポートコード：QY2207E09263 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,087,800 (USD7,350) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症のパンデミックにより、世界のオミクス系臨床試験の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にオミクス系臨床試験の世界市場のxxx％を占める「介入研究」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「腫瘍」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のオミクス系臨床試験の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのオミクス系臨床試験市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのオミクス系臨床試験市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 オミクス系臨床試験のグローバル主要メーカーには、Parexel International Corporation、Pharmaceutical Product Development (PPD)、Charles River Laboratory、ICON plc、SGS SA、Eli Lilly and Company、Pfizer、Covance、Rebus Bio、Novo Nordiskなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 オミクス系臨床試験市場は、種類と用途によって区分されます。世界のオミクス系臨床試験市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 介入研究、観察研究、拡張アクセス研究 【用途別セグメント】 腫瘍、心臓病、呼吸器疾患、皮膚病、CNS疾患、免疫、遺伝病、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - オミクス系臨床試験製品概要 - 種類別市場（介入研究、観察研究、拡張アクセス研究） - 用途別市場（腫瘍、心臓病、呼吸器疾患、皮膚病、CNS疾患、免疫、遺伝病、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のオミクス系臨床試験販売量予測2017-2028 - 世界のオミクス系臨床試験売上予測2017-2028 - オミクス系臨床試験の地域別販売量 - オミクス系臨床試験の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別オミクス系臨床試験販売量 - 主要メーカー別オミクス系臨床試験売上 - 主要メーカー別オミクス系臨床試験価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（介入研究、観察研究、拡張アクセス研究） - オミクス系臨床試験の種類別販売量 - オミクス系臨床試験の種類別売上 - オミクス系臨床試験の種類別価格 ・用途別市場規模（腫瘍、心臓病、呼吸器疾患、皮膚病、CNS疾患、免疫、遺伝病、その他） - オミクス系臨床試験の用途別販売量 - オミクス系臨床試験の用途別売上 - オミクス系臨床試験の用途別価格 ・北米市場 - 北米のオミクス系臨床試験市場規模（種類別、用途別） - 主要国別のオミクス系臨床試験市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのオミクス系臨床試験市場規模（種類別、用途別） - 主要国別のオミクス系臨床試験市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のオミクス系臨床試験市場規模（種類別、用途別） - 主要国別のオミクス系臨床試験市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のオミクス系臨床試験市場規模（種類別、用途別） - 主要国別のオミクス系臨床試験市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのオミクス系臨床試験市場規模（種類別、用途別） - 主要国別のオミクス系臨床試験市場規模（トルコ、サウジアラビア） ・企業情報 Parexel International Corporation、Pharmaceutical Product Development (PPD)、Charles River Laboratory、ICON plc、SGS SA、Eli Lilly and Company、Pfizer、Covance、Rebus Bio、Novo Nordisk ・産業チェーン及び販売チャネル分析 - オミクス系臨床試験の産業チェーン分析 - オミクス系臨床試験の原材料 - オミクス系臨床試験の生産プロセス - オミクス系臨床試験の販売及びマーケティング - オミクス系臨床試験の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - オミクス系臨床試験の産業動向 - オミクス系臨床試験のマーケットドライバー - オミクス系臨床試験の課題 - オミクス系臨床試験の阻害要因 ・主な調査結果 |
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Market Analysis and Insights: Global Omics Based Clinical Trials Market
The global Omics Based Clinical Trials market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Interventional Studies accounting for % of the Omics Based Clinical Trials global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Oncology segment is altered to an % CAGR throughout this forecast period.
China Omics Based Clinical Trials market size is valued at US$ million in 2021, while the North America and Europe Omics Based Clinical Trials are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Omics Based Clinical Trials landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Omics Based Clinical Trials market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Omics Based Clinical Trials market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Omics Based Clinical Trials market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Omics Based Clinical Trials market.
Global Omics Based Clinical Trials Scope and Market Size
Omics Based Clinical Trials market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Omics Based Clinical Trials market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
By Company
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Omics Based Clinical Trials Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Interventional Studies
1.2.3 Observational Studies
1.2.4 Expanded Access Studies
1.3 Market by Application
1.3.1 Global Omics Based Clinical Trials Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Respiratory Diseases
1.3.5 Skin Diseases
1.3.6 CNS Diseases
1.3.7 Immunology
1.3.8 Genetic Diseases
1.3.9 Other Indications
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Omics Based Clinical Trials Market Perspective (2017-2028)
2.2 Omics Based Clinical Trials Growth Trends by Region
2.2.1 Omics Based Clinical Trials Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Omics Based Clinical Trials Historic Market Size by Region (2017-2022)
2.2.3 Omics Based Clinical Trials Forecasted Market Size by Region (2023-2028)
2.3 Omics Based Clinical Trials Market Dynamics
2.3.1 Omics Based Clinical Trials Industry Trends
2.3.2 Omics Based Clinical Trials Market Drivers
2.3.3 Omics Based Clinical Trials Market Challenges
2.3.4 Omics Based Clinical Trials Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Omics Based Clinical Trials Players by Revenue
3.1.1 Global Top Omics Based Clinical Trials Players by Revenue (2017-2022)
3.1.2 Global Omics Based Clinical Trials Revenue Market Share by Players (2017-2022)
3.2 Global Omics Based Clinical Trials Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Omics Based Clinical Trials Revenue
3.4 Global Omics Based Clinical Trials Market Concentration Ratio
3.4.1 Global Omics Based Clinical Trials Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Omics Based Clinical Trials Revenue in 2021
3.5 Omics Based Clinical Trials Key Players Head office and Area Served
3.6 Key Players Omics Based Clinical Trials Product Solution and Service
3.7 Date of Enter into Omics Based Clinical Trials Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Omics Based Clinical Trials Breakdown Data by Type
4.1 Global Omics Based Clinical Trials Historic Market Size by Type (2017-2022)
4.2 Global Omics Based Clinical Trials Forecasted Market Size by Type (2023-2028)
5 Omics Based Clinical Trials Breakdown Data by Application
5.1 Global Omics Based Clinical Trials Historic Market Size by Application (2017-2022)
5.2 Global Omics Based Clinical Trials Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Omics Based Clinical Trials Market Size (2017-2028)
6.2 North America Omics Based Clinical Trials Market Size by Type
6.2.1 North America Omics Based Clinical Trials Market Size by Type (2017-2022)
6.2.2 North America Omics Based Clinical Trials Market Size by Type (2023-2028)
6.2.3 North America Omics Based Clinical Trials Market Share by Type (2017-2028)
6.3 North America Omics Based Clinical Trials Market Size by Application
6.3.1 North America Omics Based Clinical Trials Market Size by Application (2017-2022)
6.3.2 North America Omics Based Clinical Trials Market Size by Application (2023-2028)
6.3.3 North America Omics Based Clinical Trials Market Share by Application (2017-2028)
6.4 North America Omics Based Clinical Trials Market Size by Country
6.4.1 North America Omics Based Clinical Trials Market Size by Country (2017-2022)
6.4.2 North America Omics Based Clinical Trials Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Omics Based Clinical Trials Market Size (2017-2028)
7.2 Europe Omics Based Clinical Trials Market Size by Type
7.2.1 Europe Omics Based Clinical Trials Market Size by Type (2017-2022)
7.2.2 Europe Omics Based Clinical Trials Market Size by Type (2023-2028)
7.2.3 Europe Omics Based Clinical Trials Market Share by Type (2017-2028)
7.3 Europe Omics Based Clinical Trials Market Size by Application
7.3.1 Europe Omics Based Clinical Trials Market Size by Application (2017-2022)
7.3.2 Europe Omics Based Clinical Trials Market Size by Application (2023-2028)
7.3.3 Europe Omics Based Clinical Trials Market Share by Application (2017-2028)
7.4 Europe Omics Based Clinical Trials Market Size by Country
7.4.1 Europe Omics Based Clinical Trials Market Size by Country (2017-2022)
7.4.2 Europe Omics Based Clinical Trials Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Omics Based Clinical Trials Market Size (2017-2028)
8.2 Asia-Pacific Omics Based Clinical Trials Market Size by Type
8.2.1 Asia-Pacific Omics Based Clinical Trials Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Omics Based Clinical Trials Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Omics Based Clinical Trials Market Share by Type (2017-2028)
8.3 Asia-Pacific Omics Based Clinical Trials Market Size by Application
8.3.1 Asia-Pacific Omics Based Clinical Trials Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Omics Based Clinical Trials Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Omics Based Clinical Trials Market Share by Application (2017-2028)
8.4 Asia-Pacific Omics Based Clinical Trials Market Size by Region
8.4.1 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Omics Based Clinical Trials Market Size (2017-2028)
9.2 Latin America Omics Based Clinical Trials Market Size by Type
9.2.1 Latin America Omics Based Clinical Trials Market Size by Type (2017-2022)
9.2.2 Latin America Omics Based Clinical Trials Market Size by Type (2023-2028)
9.2.3 Latin America Omics Based Clinical Trials Market Share by Type (2017-2028)
9.3 Latin America Omics Based Clinical Trials Market Size by Application
9.3.1 Latin America Omics Based Clinical Trials Market Size by Application (2017-2022)
9.3.2 Latin America Omics Based Clinical Trials Market Size by Application (2023-2028)
9.3.3 Latin America Omics Based Clinical Trials Market Share by Application (2017-2028)
9.4 Latin America Omics Based Clinical Trials Market Size by Country
9.4.1 Latin America Omics Based Clinical Trials Market Size by Country (2017-2022)
9.4.2 Latin America Omics Based Clinical Trials Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Omics Based Clinical Trials Market Size (2017-2028)
10.2 Middle East & Africa Omics Based Clinical Trials Market Size by Type
10.2.1 Middle East & Africa Omics Based Clinical Trials Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Omics Based Clinical Trials Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Omics Based Clinical Trials Market Share by Type (2017-2028)
10.3 Middle East & Africa Omics Based Clinical Trials Market Size by Application
10.3.1 Middle East & Africa Omics Based Clinical Trials Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Omics Based Clinical Trials Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Omics Based Clinical Trials Market Share by Application (2017-2028)
10.4 Middle East & Africa Omics Based Clinical Trials Market Size by Country
10.4.1 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Parexel International Corporation
11.1.1 Parexel International Corporation Company Details
11.1.2 Parexel International Corporation Business Overview
11.1.3 Parexel International Corporation Omics Based Clinical Trials Introduction
11.1.4 Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2017-2022)
11.1.5 Parexel International Corporation Recent Developments
11.2 Pharmaceutical Product Development (PPD)
11.2.1 Pharmaceutical Product Development (PPD) Company Details
11.2.2 Pharmaceutical Product Development (PPD) Business Overview
11.2.3 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Introduction
11.2.4 Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2017-2022)
11.2.5 Pharmaceutical Product Development (PPD) Recent Developments
11.3 Charles River Laboratory
11.3.1 Charles River Laboratory Company Details
11.3.2 Charles River Laboratory Business Overview
11.3.3 Charles River Laboratory Omics Based Clinical Trials Introduction
11.3.4 Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2017-2022)
11.3.5 Charles River Laboratory Recent Developments
11.4 ICON plc
11.4.1 ICON plc Company Details
11.4.2 ICON plc Business Overview
11.4.3 ICON plc Omics Based Clinical Trials Introduction
11.4.4 ICON plc Revenue in Omics Based Clinical Trials Business (2017-2022)
11.4.5 ICON plc Recent Developments
11.5 SGS SA
11.5.1 SGS SA Company Details
11.5.2 SGS SA Business Overview
11.5.3 SGS SA Omics Based Clinical Trials Introduction
11.5.4 SGS SA Revenue in Omics Based Clinical Trials Business (2017-2022)
11.5.5 SGS SA Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Omics Based Clinical Trials Introduction
11.6.4 Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2017-2022)
11.6.5 Eli Lilly and Company Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Omics Based Clinical Trials Introduction
11.7.4 Pfizer Revenue in Omics Based Clinical Trials Business (2017-2022)
11.7.5 Pfizer Recent Developments
11.8 Covance
11.8.1 Covance Company Details
11.8.2 Covance Business Overview
11.8.3 Covance Omics Based Clinical Trials Introduction
11.8.4 Covance Revenue in Omics Based Clinical Trials Business (2017-2022)
11.8.5 Covance Recent Developments
11.9 Rebus Bio
11.9.1 Rebus Bio Company Details
11.9.2 Rebus Bio Business Overview
11.9.3 Rebus Bio Omics Based Clinical Trials Introduction
11.9.4 Rebus Bio Revenue in Omics Based Clinical Trials Business (2017-2022)
11.9.5 Rebus Bio Recent Developments
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Details
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Omics Based Clinical Trials Introduction
11.10.4 Novo Nordisk Revenue in Omics Based Clinical Trials Business (2017-2022)
11.10.5 Novo Nordisk Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
Table 1. Global Omics Based Clinical Trials Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Interventional Studies
Table 3. Key Players of Observational Studies
Table 4. Key Players of Expanded Access Studies
Table 5. Global Omics Based Clinical Trials Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Omics Based Clinical Trials Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Omics Based Clinical Trials Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Omics Based Clinical Trials Market Share by Region (2017-2022)
Table 9. Global Omics Based Clinical Trials Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Omics Based Clinical Trials Market Share by Region (2023-2028)
Table 11. Omics Based Clinical Trials Market Trends
Table 12. Omics Based Clinical Trials Market Drivers
Table 13. Omics Based Clinical Trials Market Challenges
Table 14. Omics Based Clinical Trials Market Restraints
Table 15. Global Omics Based Clinical Trials Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Omics Based Clinical Trials Revenue Share by Players (2017-2022)
Table 17. Global Top Omics Based Clinical Trials by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2021)
Table 18. Ranking of Global Top Omics Based Clinical Trials Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Omics Based Clinical Trials Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Omics Based Clinical Trials Product Solution and Service
Table 22. Date of Enter into Omics Based Clinical Trials Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Omics Based Clinical Trials Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Omics Based Clinical Trials Revenue Market Share by Type (2017-2022)
Table 26. Global Omics Based Clinical Trials Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Omics Based Clinical Trials Revenue Market Share by Type (2023-2028)
Table 28. Global Omics Based Clinical Trials Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Omics Based Clinical Trials Revenue Share by Application (2017-2022)
Table 30. Global Omics Based Clinical Trials Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Omics Based Clinical Trials Revenue Share by Application (2023-2028)
Table 32. North America Omics Based Clinical Trials Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Omics Based Clinical Trials Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Omics Based Clinical Trials Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Omics Based Clinical Trials Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Omics Based Clinical Trials Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Omics Based Clinical Trials Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Omics Based Clinical Trials Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Omics Based Clinical Trials Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Omics Based Clinical Trials Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Omics Based Clinical Trials Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Omics Based Clinical Trials Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Omics Based Clinical Trials Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Omics Based Clinical Trials Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Omics Based Clinical Trials Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Omics Based Clinical Trials Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Omics Based Clinical Trials Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Omics Based Clinical Trials Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Omics Based Clinical Trials Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Omics Based Clinical Trials Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Omics Based Clinical Trials Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Omics Based Clinical Trials Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Omics Based Clinical Trials Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Omics Based Clinical Trials Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Omics Based Clinical Trials Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Omics Based Clinical Trials Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Omics Based Clinical Trials Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Omics Based Clinical Trials Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Omics Based Clinical Trials Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Omics Based Clinical Trials Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Omics Based Clinical Trials Market Size by Country (2023-2028) & (US$ Million)
Table 62. Parexel International Corporation Company Details
Table 63. Parexel International Corporation Business Overview
Table 64. Parexel International Corporation Omics Based Clinical Trials Product
Table 65. Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 66. Parexel International Corporation Recent Developments
Table 67. Pharmaceutical Product Development (PPD) Company Details
Table 68. Pharmaceutical Product Development (PPD) Business Overview
Table 69. Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Product
Table 70. Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 71. Pharmaceutical Product Development (PPD) Recent Developments
Table 72. Charles River Laboratory Company Details
Table 73. Charles River Laboratory Business Overview
Table 74. Charles River Laboratory Omics Based Clinical Trials Product
Table 75. Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 76. Charles River Laboratory Recent Developments
Table 77. ICON plc Company Details
Table 78. ICON plc Business Overview
Table 79. ICON plc Omics Based Clinical Trials Product
Table 80. ICON plc Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 81. ICON plc Recent Developments
Table 82. SGS SA Company Details
Table 83. SGS SA Business Overview
Table 84. SGS SA Omics Based Clinical Trials Product
Table 85. SGS SA Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 86. SGS SA Recent Developments
Table 87. Eli Lilly and Company Company Details
Table 88. Eli Lilly and Company Business Overview
Table 89. Eli Lilly and Company Omics Based Clinical Trials Product
Table 90. Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 91. Eli Lilly and Company Recent Developments
Table 92. Pfizer Company Details
Table 93. Pfizer Business Overview
Table 94. Pfizer Omics Based Clinical Trials Product
Table 95. Pfizer Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 96. Pfizer Recent Developments
Table 97. Covance Company Details
Table 98. Covance Business Overview
Table 99. Covance Omics Based Clinical Trials Product
Table 100. Covance Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 101. Covance Recent Developments
Table 102. Rebus Bio Company Details
Table 103. Rebus Bio Business Overview
Table 104. Rebus Bio Omics Based Clinical Trials Product
Table 105. Rebus Bio Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 106. Rebus Bio Recent Developments
Table 107. Novo Nordisk Company Details
Table 108. Novo Nordisk Business Overview
Table 109. Novo Nordisk Omics Based Clinical Trials Product
Table 110. Novo Nordisk Revenue in Omics Based Clinical Trials Business (2017-2022) & (US$ Million)
Table 111. Novo Nordisk Recent Developments
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Omics Based Clinical Trials Market Share by Type: 2021 VS 2028
Figure 2. Interventional Studies Features
Figure 3. Observational Studies Features
Figure 4. Expanded Access Studies Features
Figure 5. Global Omics Based Clinical Trials Market Share by Application: 2021 VS 2028
Figure 6. Oncology Case Studies
Figure 7. Cardiology Case Studies
Figure 8. Respiratory Diseases Case Studies
Figure 9. Skin Diseases Case Studies
Figure 10. CNS Diseases Case Studies
Figure 11. Immunology Case Studies
Figure 12. Genetic Diseases Case Studies
Figure 13. Other Indications Case Studies
Figure 14. Omics Based Clinical Trials Report Years Considered
Figure 15. Global Omics Based Clinical Trials Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 16. Global Omics Based Clinical Trials Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 17. Global Omics Based Clinical Trials Market Share by Region: 2021 VS 2028
Figure 18. Global Omics Based Clinical Trials Market Share by Players in 2021
Figure 19. Global Top Omics Based Clinical Trials Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2021)
Figure 20. The Top 10 and 5 Players Market Share by Omics Based Clinical Trials Revenue in 2021
Figure 21. North America Omics Based Clinical Trials Market Size YoY (2017-2028) & (US$ Million)
Figure 22. North America Omics Based Clinical Trials Market Size Market Share by Type (2017-2028)
Figure 23. North America Omics Based Clinical Trials Market Size Market Share by Application (2017-2028)
Figure 24. North America Omics Based Clinical Trials Market Size Share by Country (2017-2028)
Figure 25. United States Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Canada Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Europe Omics Based Clinical Trials Market Size YoY (2017-2028) & (US$ Million)
Figure 28. Europe Omics Based Clinical Trials Market Size Market Share by Type (2017-2028)
Figure 29. Europe Omics Based Clinical Trials Market Size Market Share by Application (2017-2028)
Figure 30. Europe Omics Based Clinical Trials Market Size Share by Country (2017-2028)
Figure 31. Germany Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. France Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. U.K. Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Italy Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Russia Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Nordic Countries Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Omics Based Clinical Trials Market Size YoY (2017-2028) & (US$ Million)
Figure 38. Asia Pacific Omics Based Clinical Trials Market Size Market Share by Type (2017-2028)
Figure 39. Asia Pacific Omics Based Clinical Trials Market Size Market Share by Application (2017-2028)
Figure 40. Asia Pacific Omics Based Clinical Trials Market Size Share by Region (2017-2028)
Figure 41. China Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Japan Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. South Korea Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Southeast Asia Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. India Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Australia Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 47. Latin America Omics Based Clinical Trials Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Latin America Omics Based Clinical Trials Market Size Market Share by Type (2017-2028)
Figure 49. Latin America Omics Based Clinical Trials Market Size Market Share by Application (2017-2028)
Figure 50. Latin America Omics Based Clinical Trials Market Size Share by Country (2017-2028)
Figure 51. Mexico Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Brazil Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Middle East & Africa Omics Based Clinical Trials Market Size YoY (2017-2028) & (US$ Million)
Figure 54. Middle East and Africa Omics Based Clinical Trials Market Size Market Share by Type (2017-2028)
Figure 55. Middle East and Africa Omics Based Clinical Trials Market Size Market Share by Application (2017-2028)
Figure 56. Middle East and Africa Omics Based Clinical Trials Market Size Share by Country (2017-2028)
Figure 57. Turkey Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 58. Saudi Arabia Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 59. UAE Omics Based Clinical Trials Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 60. Parexel International Corporation Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 61. Pharmaceutical Product Development (PPD) Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 62. Charles River Laboratory Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 63. ICON plc Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 64. SGS SA Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 65. Eli Lilly and Company Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 66. Pfizer Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 67. Covance Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 68. Rebus Bio Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 69. Novo Nordisk Revenue Growth Rate in Omics Based Clinical Trials Business (2017-2022)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
臨床試験被験者募集のグローバル市場インサイト・予測（～2028年） Clinical trial patient recruitment companies use a range of methods, from digital advertising to community partnerships, to find the right patients for your trial. The global market has noticed significant growth owing to the increasing rate of clinical trials, and the rapid growth of the medical an…- インシリコ臨床試験のグローバル市場インサイト・予測（～2028年） An in silico clinical trial, also known as a virtual clinical trial, is an individualized computer simulation used in the development or regulatory evaluation of a medicinal product, device, or intervention. While completely simulated clinical trials are not feasible with current technology and unde…
- 治験患者募集サービスのグローバル市場インサイト・予測（～2028年） Clinical trial patient recruitment companies use a range of methods, from digital advertising to community partnerships, to find the right patients for your trial. The global market has noticed significant growth owing to the increasing rate of clinical trials, and the rapid growth of the medical an…
- 臨床試験募集＆管理サービスのグローバル市場インサイト・予測（～2028年） Clinical trial patient recruitment companies use a range of methods, from digital advertising to community partnerships, to find the right patients for your trial. The global market has noticed significant growth owing to the increasing rate of clinical trials, and the rapid growth of the medical an…
- 神経変性疾患治療薬のグローバル市場インサイト・予測（～2028年） Market Analysis and Insights: Global Neurodegenerative Diseases Therapeutics Market The global Neurodegenerative Diseases Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028. Fully considering the economic change by this healt…